Scandinavian ChemoTech AB is introducing the next project within the company's product development and this product relates to pain control. D-EEPC (Dynamic-ElectroEnhanced Pain Control™ ) is a revolutionary treatment that reduces pain for patients with secondary bone cancer.
– Over 25% of all cancer patients suffer from secondary bone cancer, which could be a cause of great pain and suffering to the patient. Treatment with our product reduces the tumor volume on the metastases in the spine. This reduces pressure on the nerves, which is the reason for the unbearable pain that unfortunately many patients suffer from, says Mohan Frick, CEO at ChemoTech.
For further information, please contact:
Mohan Frick, CEO
Tele: +46 (0)10-218 93 03
Mail: [email protected]
Scandinavian ChemoTech AB (publ)
ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on NASDAQ First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.
Powered by WPeMatico